Matrix Capital Management Company, LP Portfolio

Auto-discovered active 13F filer.

SEC 13F CIK: 0001410830

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedTechnology TiltHigh Turnover how tags are computed

Q1 2025 · 4 positions · Total reported value $347.21M · Top-10 concentration 100.0% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 50.0% · 0 new · 0 cut · 1 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

In its Q1 2025 13F filing, Matrix Capital Management Company, LP disclosed 4 equity positions with a combined reported value of $347.21M. The filing implies a focused portfolio: its ten largest positions account for 100.0% of reported value. HoldingsHub classifies the profile as Small / Focused / Technology Tilt / High Turnover.

The largest disclosed positions as of Q1 2025 were GFS ($257.08M), AURA ($40.57M), MAZE ($27.37M). By sector, the heaviest allocations are Technology 74.0%, Health Care 26.0%. Versus the prior quarter, allocation shifted toward Technology (+45.6pp), Health Care (+21.3pp) and away from Industrials (-3.9pp), Other (-63.0pp).

Versus the prior quarter, Matrix Capital Management Company, LP opened 0 new positions, trimmed 0 and fully exited 1, a turnover rate of 50.0% of positions. The portfolio's overlap with the prior quarter was 50% of names.

The largest new positions opened in Q1 2025 were MAZE ($27.37M).

Of the 1 positions fully exited versus the prior quarter, the largest were ALTR ($1.36B), PRM ($83.76M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q1 2025)

  • MAZE MAZE THERAPEUTICS INCORPORATED · $27.37M

Fully Exited (vs previous quarter)

  • ALTR Altair Engineering Inc · prev qtr: $1.36B
  • PRM PERIMETER SOLUTIONS INC · prev qtr: $83.76M

Insider Transactions (Form 4)

Latest Matrix Capital Management Company, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-05-07 Sell Aura Biosciences, Inc. 6,922,870 $5.64 SEC filing

All insider transactions →

Fund Profile

Matrix Capital Management Company, LP is an SEC-registered 13F filer based in Portsmouth, NH, United States. As of Q1 2026 it reported 1 US equity positions with a combined value of $46.31M. HoldingsHub carries 11 quarters of its filings (Q3 2023–Q1 2026).

Firm Snapshot

  • Headquarters: PORTSMOUTH, NH, United States
  • SEC registration: 801-73612 (status: Approved), registered 2012-03-30
  • Regulatory AUM (Form ADV): $2.32B as of 2026-03-31
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 2 private funds, of which 1 hedge funds

Portfolio Structure

  • 1 positions · $46.31M reported value (Q1 2026)
  • Top 10 holdings = 100.0% of reported value
  • Largest position: AURA (AURA BIOSCIENCES INC) at 100.0%
  • Average position size: $46.31M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

Matrix Capital Management Rebalancing Analysis 1. Overall direction and market view: Concentrated biotechnology focus with unchanged position, suggesting high conviction in AURA's cancer therapy pipeline despite no new investments. 2. Key moves: No changes to the portfolio (0 new positions, 0% change in AURA shares), indicating stable conviction in existing holding. 3. Portfolio structure: Highly active, concentrated strategy (100% in one security) with aggressive risk profile in Health Care/Biotechnology sector. 4. Per-holding analysis: - AURA: Biotechnology company developing targeted cancer therapies (Health Care) 5. Style summary: Specialized biotechnology fund maintaining concentrated position with no rebalancing, reflecting conviction in AURA's therapeutic pipeline.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Technology 74.0%
Health Care 26.0%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 6.96M $257.08M 74.04%
74.04%
Reduce
2 6.92M $40.57M 11.68%
11.68%
Hold
3 2.49M $27.37M 7.88%
7.88%
New
4 13.96M $22.20M 6.39%
6.39%
Hold

FAQ

What did Matrix Capital Management Company, LP buy in 2025-Q1?

In its 2025-Q1 13F filing, Matrix Capital Management Company, LP reported 4 equity positions worth $347.21M in aggregate; its largest disclosed positions were GFS ($257.08M), AURA ($40.57M), MAZE ($27.37M).

How large is Matrix Capital Management Company, LP's portfolio?

Matrix Capital Management Company, LP reported $347.21M of long equity holdings across 4 positions as of 2025-Q1. Top-10 holdings account for 100.0% of reported value.

What is Matrix Capital Management Company, LP's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Technology Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/matrix-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →